RecruitingPhase 1NCT06484062
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Studying Acute myeloid leukemia with recurrent genetic anomaly
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Evan C ChenDana-Farber - Harvard Cancer Center LAO
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 54 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (18)
- Yale University, New Haven, Connecticut, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
- Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Siteman Cancer Center-South County, St Louis, Missouri, United States
- Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
- Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Memorial Sloan Kettering Commack, Commack, New York, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06484062 on ClinicalTrials.gov